© Vesalius BiocapitalDesigned by Intrigo
Vesalius Biocapital offers venture capital
to young European innovative life science companies
Amakem is using it’s Localized Drug Action platform for the development of kinase inhibitors. The primary focus is on eye disease.
Status: Investing phase